Join
Live feed
·
PRReleasevia Quantisnow
Galmed Pharmaceuticals Ltd. logo

Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol

ByQuantisnow·Wall Street's wire, on your screen.
GLMD· Galmed Pharmaceuticals Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GLMD (Galmed Pharmaceuticals Ltd.) and more on Quantisnow.